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A B S T R A C T
Background: Renal cell carcinoma account for 3% of all cancers, with peak incidence between 60 and 70 years of
age predominantly aﬀecting male population. Renal carcinoma is the most common malignancy of kidney
constitutes for 80–90% of renal neoplasm with an overall 45% ﬁve years survival rate. Majority are diagnosed
incidentally during investigation for other disease process of abdomen. Classical triad of gross hematuria, pain
and palpable mass in abdomen is rare accounting to only 6–10%. Treatment of early stages of disease i.e.
localized disease is partial or radical nephrectomy. Most common metastasis in RCC occurs to lung, followed by
bone involvement in 20–35%, lymph nodes, liver, adrenal gland and brain. In metastatic disease median survival
rate of patient is about eight months with 50% mortality rate within ﬁrst year of life, ﬁve years survival rate is
10%. Skeletal metastasis are very destructive in patients with renal cell carcinoma compromising bone integrity
leading to skeletal related events including pains, impending fractures, nerve compressions, hypercalcemia and
even pathological fractures which may require surgical interventions and other therapy. In addition to skeletal
complications, presence of bone metastases in RCC has negative impact on progression free survival and overall
survival of patients treated with systemic therapies.
Objective: In this review we discuss pathophysiology of tumor metastasis, diagnosis, management and Case
examples of metastatic renal cell carcinoma.
Conclusion: Incidence of metastatic renal carcinoma is increasing. Overall prognosis of patient with advanced
RCC is poor, emphasizing the importance of early detection and prompt treatment of primary lesion in its early
stage. Advancement in targeted therapy in recent decades had made some improvement in treatment of SREs
and has helped in improving patent's quality of life but still we are in need of further improvement in treatment
modalities to cure disease thereby decreasing morbidity and mortality.
1. Introduction
Renal cell carcinoma account for 3% of all cancers and commonly
occurs in western countries [1]. Its peak incidence found between 60
and 70 years of age and is more common in men than women. Renal
carcinoma is the most common malignancy of kidney constitutes for
80–90% of renal neoplasm with an overall 45% ﬁve years survival rate.
Renal cell carcinoma [RCC] is subdivided into clear cell, papillary and
chromophobe but clear cell variety is the most common. Due to in-
creased use of modern diagnostic modalities of choice like ultrasound
and CT scan, diagnosis of RCCs has increased in early stages [2] and
majority are diagnosed incidentally during investigation for other dis-
ease process of abdomen [4]. Classical triad of gross hematuria, pain
and palpable mass in abdomen is rare accounting to only 6–10% [3].
Ultrasound and cross sectional imaging like CT scan and MRI are
needed to establish diagnosis. Treatment of early stages of disease i.e.
localized disease is partial or radical nephrectomy. Recurrent lesion
[> 10 years] is rare in RCC [4]. The recurrence rate are about
10.5%–21.6% at 15 and 20 years respectively as described by Miyao
et al. [5].
Most common metastasis in RCC occurs to lung, followed by bone
involvement in 20–35% [6], lymph nodes, liver, adrenal gland and
brain. In metastatic disease median survival rate of patient is about
eight months [7] with 50% mortality rate within ﬁrst year of life, ﬁve
years survival rate is 10% [8].
Skeletal metastasis is very destructive in patients with renal cell
carcinoma leading to mainly osteolytic lesions that compromise bone
integrity and negatively impact patients outcome. Skeletal involvement
in RCC is associated with skeletal related events [SRE] including pains,
impending fractures, nerve compressions, hypercalcemia and even pa-
thological fractures which may require surgical interventions and other
therapy [9, 10]. Swanson et al. studied 947 patients with renal cell
carcinoma and skeletal metastasis was found in 26.7% of patients
which mostly involved spine, pelvis and proximal femur [11]. In
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addition to skeletal complications, presence of bone metastases in RCC
has negative impact on progression free survival and overall survival of
patients treated with systemic therapies.
Santoni et al. investigated patients with bone metastases from RCC
and found patients' age, ECOG performance status, histology, MSKCC
prognostic score, presence of concomitant metastasis and time from
nephrectomy to bone metastases [TTBM] to be signiﬁcant factors as-
sociated with prognosis [12].
Kume et al. analyzed 94 patients with mRCC to bone and on a
multivariate analysis found that sarcomatoid diﬀerentiation of RCC,
vertebral bone involvement, extra-osseous metastases, alkaline phos-
phatase> 1.5 times normal and C-reactive protein> 0.3 mg/dl were
signiﬁcant risk factors that adversely eﬀect overall survival [13].
2. Pathophysiology of tumor metastasis
Skeletal metastatic lesions are divided into three types: Osteolytic,
osteoblastic and mixed. Activity of osteoclasts is responsible for osteo-
lytic lesion and their activating mechanism varies according to diﬀerent
types of primary malignancies. Osteoclasts are derived from hemato-
poietic stem cells [monocyte-macrophage lineage] and mainly they
resorb mineralized bone matrix by creating microenvironment and ul-
timately undergo apoptosis. In normal metabolism, bone micro-en-
vironment enhances osteoclast production by forming diﬀerent mole-
cules like macrophage colony stimulating factors and receptor activator
of nuclear factor kB [RANK] and its ligand [RANKL] by stromal cells,
osteoblast, activated T-cells, tumor cells and osteoclast precursor cells.
Bone metastases develop by occupation of bone erythropoietic system
by cancer cells. Interaction of tumor cells and bone micro-environment
induces immune cells to release factors that attract and stimulate os-
teoclasts thereby causing increased bone turnover and destruction [9].
The discovery and characterization of the essential cytokines for
osteoclast biology, receptor activator of nuclear factor [NF]-kB ligand
[RANKL], its receptor RANK, and its decoy receptor osteoprotegerin
[OPG] have led to a concept of bone metabolism. With accumulating
evidence of the role of the OPG/RANKL/RANK system in normal ske-
letal physiology, it became clear that many clinically relevant metabolic
bone diseases in humans, including inﬂammatory bone diseases e.g.,
rheumatoid arthritis, malignant bone tumors e.g., myeloma or osteo-
lytic metastases and diﬀerent forms of osteoporosis are related to, or
caused by, alterations of the OPG/RANKL/RANK system [9].
3. Bone cells and immune system
A complex system of interaction exists between bone and body
immune system at molecular level. This includes RANK, RANKL and
natural decoy receptor osteoprotegerin [OPG]. Higher serum ratio of
RANKL/OPG promotes osteoclastogensis [14]. Mikami at el [15]. stated
that expression of RANKL and RANK is directly related to stage of
primary lesion and metastasis to bone and other organ.
4. Bone cells and renal cell carcinoma
The pathogenesis of skeletal metastasis in RCC is same as for breast
cancer. A vicious cycle exists between tumor cells and bone. Osteoclast
activation due to presence of malignant cells lead to bone destruction
with secretion of diﬀerent bone-derived growth factors and cytokines
which facilitate cancer cell proliferation and enhance tumor growth.
These include transforming growth factor-beta [TGF-β], ﬁbroblast
growth factors [FGF], insulin like growth factors and bone morpho-
genic protein and many more. These factors not only stimulate the local
growth of RCC cells but also circulate and stimulate remote metastatic
growth [16]. Tumor cells are responsible for release of prostaglandins,
activated vitamin D, tumor necrosis factor [TNF], para-thyroid hor-
mone and its related peptide, these activates osteoblast and stromal
cells on bone marrow by interacting through RANKL system and
ultimately stimulates osteoclast activity.
5. Osseus metastasis in RCC and role of diﬀerent molecular
mediators
Bone is a source of numerous growth factors, thus enabling survival
of metastatic tumor cells. Kominsky et al. [17] studied that RCC bone
metastasis cells can be stimulated by transforming growth factor-beta1
[TGF-1] in vivo. This interaction increases tumor growth and bone
destruction. They also concluded that inhibition of TGF-1 helpful in
treatment of RCC bone metastasis.
Weber et al. [18] demonstrated that growth factor signaling
pathway which includes epidermal growth factor receptors [EGF-R]
and transforming growth factor beta receptor [TGF-betaR] play a vital
role in RCC- activated osteoclast bone resorption and inhibition of this
signaling pathway decreases RCC bone metastasis.
Joeckel et al. [19] demonstrated a positive relationship between
extracellular calcium concentration and RCC with the help of calcium
sensing receptor [CaSR]. Higher expression was found in RCC and
calcium treatment leads to increase RCC proliferation.
PTHrP is a polypeptide and is released by normal as well as ma-
lignant cells, regulating growth, diﬀerentiation and death. Massfelder
et al. [20] studied that blocking of PTHrP with antibodies or antag-
onizing PTHrP receptors increases cell death in RCC. Talon et al. [21]
demonstrated blocking PTHrP system can be employed for therapeutic
treatment of RCC in clinical setting.
There are many more molecules which involves in regulation of
renal cell carcinoma, immune system and skeletal metastasis. These
include isuline mRNA binding protein-3 [IMP3][22], caderrin-11 [23],
AKT/integrin-5 signaling system [24], MicroRNAs [miRNAs] [25] and
matritase [26]. Studies are still needed for better understanding of more
signaling pathways to improve prognosis of RCC.
6. Diagnosis of RCC skeletal metastasis
Early diagnosis and prompt treatment reduces long term skeletal
complications [6]. Like other malignancies, bone scan is the imaging
modality of choice to determine metastatic bone growth for patient
with RCC. Plain radiograph shows pure lytic lesion and helpful to
identify impending or established fracture.
Bone scan shows osteoblastic activity in the form of hot spots [27].
In osteolytic lesion, compensatory osteoblastic activities increase, hence
producing hotspots even in lytic lesion. Therefore early lesions in RCC
have diﬃculty in detection by bone scan. Patient may present with
hyper-calcaemia, spinal cord or nerve root compression, pain with
impending fracture or pathologic fracture. Non-symptomatic patients
produce few positive results. Hence bone scintigraphy is more helpful in
symptomatic patients.
Positron emission tomography [PET] and whole body MRI are also
used for diagnosis of lesion. It can quantify lesion and is helpful for
monitoring during followup. Some studies may describe that PET may
replace bone scanning but it is expensive [28].
MRI is the investigation of choice in lesion with cord compression.
Studies have proved superiority of MRI over PET in detecting renal
bone metastasis besides non-requirement of any labeling agent [radio-
pharmaceutical Drug].
7. Management
Metastatic lesions are commonly encountered with local pain, spinal
cord compression/deﬁcit, fracture and hypercalcaemiaof malignancy.
Goal of treatment includes prevention of theses complication, pain
palliation and improvement in quality of life [29]. Management of le-
sion involves adequate history and physical examination and metastatic
workup. Multidisciplinary approach should de needed, comprising of
orthopedic surgeon, urologist, radiologist, pathologist, radiation
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oncologist and medical oncologist.
8. Medical treatment
Tumor cells produce activation of osteoclast through RANKL sig-
naling pathways and other molecular mechanism, as described earlier.
Medical management is aimed to prevent these signaling pathways and
ultimately prevent activation of osteoclast. Two classes of drug are
commonly used to suppress osteoclast mediated bone resorption. These
include: bisphosphonate and denosumab.
9. Bisphosphonate
Development of bisphosphonate has improved quality of life of
patients and widely used treatment of diﬀerent malignancies including
RCC. It inhibits osteoclastic activity thereby decreasing bone resorp-
tion. Various clinical trials have been conducted to determine safety
and eﬃcacy of the drug [30]. Favorable results were obtained in the
form of reduction in skeletal related events [SREs] like pain reduction
[31]. Diﬀerent types of bisphosphonate have been prescribed for SREs
prevention including clodronate, pamidronate, ibandronate and zole-
dronic acid. Zoledronic acid is a potent inhibitor of osteolytic activity
and studied in various clinical trials for use in reducing SREs in patients
with metastatic lesions from breast [32], castration-resistant prostate
cancer [33], lung and RCC [34]. Now Zoledronic acid is widely used for
treatment of metastatic bone disease [35] however, compared to bone
metastases from other tumors, this drug has been under-utilized for
management of metastases in RCC [36].
A study conducted by Broom et al. [37] demonstrated improved
results of adding Zoledronic acid to targeted therapy [everolimus and
zoledronic acid] in patient with RCC bone metastasis. After 12 weeks of
administration, median progression-free survival [PFS] was 7.5 months
with everolimus plus zoledronic acid and 5.4 months with everolimus.
The median time to ﬁrst SRE was 9.6 months among patient on com-
bination therapy and 5.2 months on single therapeutic agent [ever-
olimus][38]. They concluded that addition of zoledronic acid to ever-
olimus signiﬁcantly reduced bone resorption and may prolong tumor
control. Zoledronic acid also induces apoptotic cell death of renal
cancer cell lines in vitro [36].
Both pre-clinical and clinical data suggests that bisphosphonates
have potential direct antitumor eﬀects and prevent tumor progression
of RCC. The also improve the outcome i.e. response rate, progression
free survival and overall survival of systematic targeted therapy for
mRCC [39].
Mckay et al. did a pooled analysis from clinical trials database
[largest to-date] and evaluated the impact of bone metastases and bi-
sphosphonate therapy on outcomes in mRCC. The study included 2749
patients treated with diﬀerent modern agents of targeted therapy i.e.
Sunitinib, Sorafenib, Axitinib, Temsirolimus, Temsirolimus + INF-α or
INF-α alone. Presence of bone metastases was associated with shorter
overall survival in all risk groups compared to those without metastases
[13.2 vs 20.2 months] and bisphosphonate therapy did not improve
progression free survival or overall survival compared to those who did
not receive bisphosphonates [40].
Patient should be counseled about adverse event of therapy. Flu like
symptoms is common in acute phase and can be managed with simple
analgesia. Renal toxicity can occur and can be managed with dose
adjustment and require special consideration in case of RCC [41]. A
potentially serious complication is osteonecrosis of jaw which is rare
[42] but common in combination therapy [43,44]. It is recommended
that patients should have a regular dental examination before and
during treatment [45].
10. Denosumab
As discussed previously, RANK-L is a potent mediator for
osteoclastic mediated bone destruction and inhibition of this signaling
pathway system decreases bone resorption. Denosumab is a human
monoclonal antibody that binds to RANKL and inhibits bone resorption
in patients with advanced cancers and those with failure of bispho-
sphonate treatment.
A large phase III trial including 800 patients with> 100 patients
with bone metastases from RCC demonstrated that denosumab is non-
inferior to zoledronic acid with regard to overall survival, disease
progression and adverse events [46].
Lipton et al. [47]analyzed 3 randomized phase III trials to evaluate
eﬃcacy and safety of denosumab versus zolendronic acid for patients
with bone metastasis [48,49]. Denosumab was found to be superior to
Zoledronic acid in delaying time to ﬁrst SRE by a median 8.21 months
and reduced the risk of ﬁrst SRE by 17%. Denosumab did not require
monitoring, dose modiﬁcation, or withholding based on renal functions
and it was not associated acute phase reactions. However hypo-cal-
caemia was more common with denosumab. Rate of osteonecrosis was
similar in both drugs.
11. Other drugs
11.1. Systemic therapy for metastatic disease
Several systemic agents are available for treatment for metastatic
renal cell carcinoma. Medroxy-progesterone [Progestational agents]
have been found to have symptomatic improvement with very little
antitumor eﬀect, with evidene of 5–6% overall response rate [50]. RCC
are chemo and radio-resistant tumors. Combination of chemotherapy
and cytokine has not produced any drastic diﬀerence, so the scope of
chemotherapy is very narrow in metastatic renal cell carcinoma. Im-
munotherapy with Interlukin 2 and Interferon-a [IFN-a] has modestre
result with 7%–27% response rate. [51], patients with good Motzer
criteria, clear cell variety and only lung metastasis has the best re-
sponse.
11.2. Targeted therapy
Advancements in the molecular biology of RCC has led to the better
understanding of biological pathways and their relationship to tumor
progression, inhibition of those pathways by targeted therapy can be
beneﬁcial in tumor control. These agents include multikinase inhibitors
like Sunitinib and Sorafenib, humanized monoclonal antibody i.e.
Bevcizumab and mTOR inhibitors like Temsirolimus. Vascular en-
dothelial growth factor [VEGF] with its receptor and mammalian target
of rapamycin [mTOR] pathways as relevant therapeutic targets to renal
cell carcinoma.
VHL is a tumor suppressor gene that has a pivotal role in patho-
genesis of RCC. The product of gene [pVHL] mediates the cellular re-
sponses to oxygen deprivation [52].
Under normoxic conditions, pVHL recognizes the hydroxylated hy-
poxia inducible factor [HIF]and targets it to degradation. Its mutation
leads to formation of defective von Hippel-Landau protein and HIF
[hypoxia-inducible factor] is not degraded leading to accumulation
with the cell. This leads to activation of pro-angiogenic genes with over
expression of VEGF, platelet-derived growth factor [PDGF], trans-
forming growth factor alpha [TGF-α] and basic ﬁbroblast growth factor
[b-FGF] genes, which in turn promotes tumor angiogenesis, prolifera-
tion and metastasis. Activation of the mTOR pathway also leads to HIF
production and is associated with angiogenesis. mTOR inhibitors act
proximally by decreasing the levels of HIF rather than on pro-angio-
genic factors.
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12. VEGF inhibiting drugs
12.1. Sunitinib
Sunitinib is an inhibitor of the tyrosine-kinase fraction of the VEGF
family of receptors. Motzer et al. in a phase III trial compared sunitinib
with interferon alfa and showed objective response rate of 39% vs 8%
and progression free survival 11 months vs 5 months. Overall survival
data reported 26.4 months versus 21.8 months for Sunitinib-treated vs
interferon-treated patients respectively [53]. Sunitinib has emerged as a
front-line standard of care in metastatic renal cell carcinoma with a
better response rate balanced for toxicity. In a mouse model, Maita
et al. showed inhibitory eﬀect of Sunitinib against progression of renal
cell cancer bone metastasis [54]. Karaca et al. demonstrated a reduction
in para-neoplastic hypercalcemia with Sunitinib therapy for metastatic
RCC which may indirectly reﬂect bone positive eﬀect [55].
Zolnierek et al. analyzed data from 3 randomized trials and two
other studies comparing the eﬀect of interferon alpha, sunitinib and
sorafenib on occurrence and progression of bone metastases in RCC and
found sunitinib to be more eﬀective than other 2 drugs at decreasing
the formation and prolongation of time to occurrence of new bone le-
sions [56]. Xiaolin et al. found that oligometastatic state of bone me-
tastatsis [with less than 5 sites] treated with sunitinib had a favorable
outcome for renal cell carcinoma [57].
12.2. Sorafenib
Sorafenib is a small molecule inhibitor of VEGF and related re-
ceptors, and also inhibits an intracellular signaling enzyme raf kinase.
In a phase III trial, patients with treatment-refractory metastatic renal
cell carcinoma noted improvement in progression-free survival of 5.5
months in the sorafenib group versus 2.8 months in the placebo group
[58].
12.3. Pazopanib
It is an oral angiogenesis inhibitor targeting VEGF receptor, PDGF
receptor, and c-KIT. In a recent prospective randomized trial of pazo-
panib versus placebo in treatment naive or cytokine-treated mRCC
patients, there was a signiﬁcant improvement in progression-free sur-
vival and tumor response, 9.2 months vs 4.2 months [59].
12.4. Bevacizumab
Bevacizumab is a monoclonal antibody that binds and neutralises
circulating VEGF protein. Its activity is popularized after large multi-
centre trials making its mark as a front line therapy in low and inter-
mediate risk groups. In a phase 3 trial Escudier et al. compared bev-
acizumab plus IFN-α with IFN-a monotherapy. The median overall
response rate was 31% versus 13% for IFN-α only. Median progression-
free survival increased signiﬁcantly from 5.4 months with IFN-α to 10.2
months for bevacizumab plus IFN-α [60].
13. mTOR inhibiting drugs
13.1. Temsirolimus
Temsirolimus is an inhibitor of speciﬁc mammalian target of rapa-
mycin [mTOR], a molecule implicated in several tumor promoting in-
tracellular signaling pathways.Hudes et al. in a phase III trial, rando-
mized patients with high risk metastatic renal cell carcinoma to receive
ﬁrst-line treatment with temsirolimus or IFN-a monotherapy or
temsirolimus + IFN-α. In the temsirolimus group, overall survival was
10.9 mo versus 7.3 mo in the IFN-α group [61].In patients treated with
combined temsirolimus plus IFN-a, overall survival was not sig-
niﬁcantly improved.
13.2. Everolimus
Everolimus is an oral mTOR inhibitor. Motzer et al. in a phase 3
study compared everolimus versus placebo in metastatic renal cell
carcinoma, who had failed previous targeted theapies along with best
supportive care. The median progression-free survival was 4 months
with everolimus versus 1.9 months with placebo [62].
13.3. Eﬀects of targeted agents on bone metastases in RCC
Bone metastases require special consideration regarding lesion
measurability according to Response Evaluation Criteria in Solid Tumor
[RECIST] criteria [63]. Bone scans and plain x-ray ﬁlms are not con-
sidered adequate imaging technique to measure bone lesions while
cross sectional imaging like CT or MRI are considered for evaluation of
lesions if soft tissue component meets the deﬁnition of measure ability.
In many studies, the assessment of bone metastases are subjective
rendering comparisons diﬃcult. In many clinical trials using targeted
therapy in mRCC, patients with bone-only metastases were excluded as
no objective bone endpoints have been measured [39].
13.4. Surgical management
Patient with isolated bony metastasis, radical surgery has long term
response. Patient has better survival with absence of pathological
fracture, single metastasis and tumor free resection [64].For multiple
metastases to bone, orthopedic intervention provides palliation. Sur-
gery in such circumstances is helpful in reducing risk of impending
fracture, to treat pathological fracture, emergency spinal decompres-
sion and to decrease spinal instability [6].
Metastasis from renal cell are very aggressive, osteolytic lesions
with cortical destruction without periosteal reaction. Spine and long
bones are exposed to pathological fracture with very little potential for
spontaneous union.
14. Angioembolization
Metastases from renal cell carcinoma are very hypervascular in
more than 65% cases equally similar to the primary neoplasm in vas-
cularity [65]. Several reports also demonstrated the eﬀectiveness of
transcatheter intra-arterial embolization of the hypervascular bone
metastases. Pre-operative embolization can contribute to reduction of
pain, decrease the blood loss during surgery and transfusion require-
ments. Chatziioannou et al., in 2000 noted mean blood loss of
535 ± 390ml in patients with complete embolization as compared to
1247 ± 1047ml with incomplete embolization, concluding that suc-
cessful embolization leads to signiﬁcant reduction of blood loss during
surgery [66].
15. Nephrectomy
Cyto-reductive nephrectomy is performed in patients with meta-
static renal cell carcinomato decrease the systemic issues including
pain, hypercalcemia, hypertension and erythrocytosis. Data from the
pre-targeted therapy era showed that cytoreductive nephrectomy had a
role in metastatic renal cell carcinoma, increasing life expectancy by
approximately 6 months in selected patients only and showed regres-
sion of metastatic lesions in 1–2% cases [67]. The role of adjuvant
nephrectomy for the purpose of inducing spontaneous regression of
metastatic lesions is questionable in the era of targeted therapy.
16. Resection of metastatic foci
A solitary metastasis with renal cell carcinoma is rare and has a
reported incidence of less than 5% [68]. Resection of metastatic foci is
also a surgical option that can be considered in selected patients.
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Resection of the primary tumor and solitary metastasis should be con-
sidered as this treatment can produce some long term survivors. Sur-
gery for metastatic foci may also be considered for palliation, in pre-
sence of large lesions, progressive bony destruction, severe
uncontrollable pain, instability or impending fracture.
17. Impending and pathologic fractures
Any skeletal lesion may cause a pathologic fracture. Certain criteria
for selecting patients for prophylactic ﬁxation have gradually evolved.
Early eﬀorts were based solely on retrospective observations of patho-
logic fractures in the proximal femur and hip, as this area is related to
signiﬁcant morbidity and mortality.
The ﬁrst set of combined guidelines for prophylactic ﬁxation of
proximal femur were presented in 1986 as: [1] greater than 50% cor-
tical destruction seen on CT, [2] a lytic lesion of the proximal
femur > 2.5 cm in diameter and [3] avulsion of the lesser trochanter
[69]. While these guidelines were helpful for lytic lesions of the femur,
they failed to account for other patterns of mixed or permeative lesions
and would not be readily applied to other sites. These guidelines could
not account for the lesions suitable for nonsurgical managements and
adjuvant therapy [65].
Mirels proposed a scoring system to recommend for or against the
prophylactic internal ﬁxation of impending fractures. It is based on four
characteristics, site of lesion, nature of lesion, size of lesion and pain
[70]. All the features were assigned progressive scores ranging from 1
to 3. Prophylactic ﬁxation is highly indicated for a lesion with an
overall score of 9 or greater (Table 1).
With the evolution of treatment modalities the survival of these
patients with metastatic disease beneﬁtting from these palliative pro-
cedures is improving. Management must be individualized keeping the
balance between beneﬁts of surgery and risks associated with operating
on a patient with limited life expectancy and suboptimal medical con-
dition. All extremities must be carefully examined before embarking on
a course of treatment. Isolated fractures in upper extremities which are
non weight bearing can be managed with palliative radiotherapy,
casting or bracing. Whereas patients with additional lower-extremity
lesions requires greater use of the upper extremities for transfers and
crutch or walker-assisted ambulation, which justiﬁes the surgical in-
tervention [71].
The goals of surgical ﬁxation are to relieve pain, improve function,
facilitate nursing care and improve psychological well-being. This re-
quires a diﬀerent approach from that used for non-neoplastic lesions, as
bony union almost never occurs without surgery and radiotherapeutic
treatment.These patients do not tolerate multiple procedures so im-
mediate ﬁxation must be obtained at the time of surgery. The basic
principle of surgical management is internal ﬁxation or prosthetic re-
placement combined with PMMA. Cementation permits immediate
stability and early mobilization and pain reduction. At least 2 months of
survival should be expected for surgery to be indicated [72]. The use of
local cryotherapy, using liquid nitrogen, at the time of surgery, or
polymethyl methacrylate, can also be considered [73]. There is a sug-
gestion that the number of viable tumor cells may be reduced by the
heat generated by polymethyl methacrylate, thereby decreasing the
chance of local recurrence.
Prostheses can be used in certain circumstances and reconstruction
of areas not amenable to internal ﬁxation, including the articular
surfaces, the proximal femur, the proximal tibia, and the proximal
humerus [74]. These devices can be used in arthroplasty for the hip,
knee and shoulder and modular diaphysis replacement systems for
segmental long bone defects. Improvement in design of these prosthesis
has expanded the horizon of these replacement arthroplasty. Even for
low-demand patients, internal ﬁxation of impending and pathological
fractures of the femoral head and neck has an unacceptably high risk of
failure due to the high stresses across the proximal femur.Peri-tro-
chanteric lesions can be reconstructed using a calcar replacement and
proximal femur replacement hip implants to address bone loss and high
stresses [75]. Certain principles should be followed when the prosthetic
replacement is considered; patient's estimated survival should exceed
the time needed for recovery from the operation. The reconstruction
should be stable enough to permit full weight-bearing immediately
after the procedure and must be durable enough to last the expected
lifetime of the patient. Planned reconstruction should address areas of
weakened bone that are present at operation, as well as areas that are
likely to be weakened subsequently.
18. Case examples
18.1. Case 1
55 year gentleman with history of radical nephrectomy for renal cell
carcinoma presented with solitary painful metastasis in right peri-
trochanteric region managed with wide margin resection and prosthetic
reconstruction with proximal femoral replacement hip Arthroplasty
Fig. 1.
18.2. Case 2
80 year old gentleman known case of RCC, post nephrectomy, un-
derwent intramedullary nailing of left femur as a palliative procedure
for pathologic fracture. 12 month follow-up xray demonstrates re-
sorption of bone Fig. 2.
18.3. Case 3
75 year gentleman, known case of metastastatic renal cell carci-
noma with deposits to lungs and bone, underwent left nephrectomy 7
years back, sustained pathological proximal humerus fracture managed
by internal ﬁxation with poly methyl methacrylate Fig. 3.
19. Radiotherapy[RT]
Major role of radiotherapy is to provide palliative treatment. It is
very eﬀective in painful bone metastasis and nerve or spinal cord de-
compression. Although tumor is considered as a radioresistant but ad-
vances in radiotherapy technologies such as intensity modulation RT,
stereotactic body RT and stereotactic radiosurgery [SRS], have made
this possible to deliver high doses of radiation with local control may
exceed 90% for SRS. Thus this provides excellent palliation [76,77]. A
study conducted by Reichel et al. [78] revealed radiotherapy has pro-
mising eﬀects in short term pain control, preventing fractures and
avoiding need for surgery in renal cell carcinoma patients with multiple
bone metastasis.
Treatment of inoperable painful metastatic lesions is considered
conservative which may employ radiotherapy, chemotherapy and an-
algesia [79]. Recently minimally invasive techniques are being used to
control painful lesions. These techniques may include ethanol [80],
laser, cryo-ablation [81], microwave [82] and radiofrequency ablation
[83].
20. Conclusion
Incidence of metastatic renal carcinoma is increasing with
Table 1
Mirel's scoring system [71].
Score Site of lesion Size of lesion Nature of lesion Pain
1 Upper limb <1/3 of cortex Blastic Mild
2 Lower limb 1/3-2/3 of cortex Mixed Moderate
3 Trochanteric region > 2/3 of cortex Lytic Functional
M. Umer et al. Annals of Medicine and Surgery 27 (2018) 9–16
13
increasing incidence of primacy lesion. Studies show 85 %of patient
with metastatic RCC may experience SREs related complications in
their life with a mean no. of> 2 events per patient [84]. These events
increase economic burden, decrease quality of life and ultimately en-
hance morbidity and mortality. Overall prognosis of patient with ad-
vanced RCC is poor; this emphasizes on importance of early detection
and prompt treatment of primary lesion in its early stage. Advancement
in targeted therapy in recent decades had made some improvement in
treatment of SREs and has helped in improving patent's quality of life
but still we are in need of further improvement in treatment modalities
to cure disease thereby decreasing morbidity and mortality.
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